Testing effectiveness (Phase 2)Not Yet RecruitingNCT07382739
What this trial is testing
Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
Who this might be right for
Phase 2Radiotherapy-Induced Immune PrimingElranatamab+4 more
M.D. Anderson Cancer Center 34